Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDB-001 in Progressive Severe COVID-19
NCT04449588Phase 3Terminated
- Sponsor
- Staidson Biopharmaceutical
- Start
- Jul 2020
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of BDB-001 in COVID-19 pneumonia, sponsored by Staidson Biopharmaceutical. Started Jul 2020; status: terminated.
02
Drugs
BDB-001
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04449588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04449588.